Synergistic control of acute respiratory pathogens by bacteriophage and the innate immune response
Synergistic control of acute respiratory pathogens by bacteriophage and the innate immune response
批准号:
10663212
负责人:
Laurent DEBARBIEUX
金额:
$48.18万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-08-22 至 2024-07-31
关键词:
AcuteAcute PneumoniaAcute respiratory infectionAddressAnimalsAntibioticsBacteriaBacterial InfectionsBacteriophagesBiological ModelsCellsClinicalClinical TrialsComputer SimulationCritical IllnessCytolysisDataDevelopmentDoseEcologyEffectivenessEffector CellEnvironmentExposure toFailureFutureGram-Negative BacteriaHospitalsHybridsImmuneImmune responseImmune signalingImmune systemImmunocompetentImmunologic Deficiency SyndromesImmunologyIn VitroIndividualInfectionInnate Immune ResponseInnate Immune SystemInterdisciplinary StudyJointsLymphoidLyticMeasurementMeasuresMetabolic Clearance RateMethodsMicrobeModelingMulti-Drug ResistanceMusNon-linear ModelsNonlinear DynamicsOutcomePathogenicityPatientsPneumoniaPopulationProliferatingPseudomonas aeruginosaPublic HealthResearchResearch PersonnelResistanceResolutionRespiratory DiseaseRespiratory Tract InfectionsRiskScheduleSystemTarget PopulationsTechniquesTestingTherapeuticTimeTranslatingTreatment EfficacyTreatment FailureUnited StatesViralVirusWorkacute infectionbacterial resistanceclinical translationcommensal bacteriacontrol theorycurative treatmentsdata integrationdensitydesigndosagedrug resistant pathogendynamic systemexperimental analysisexperimental studyimmunological statusimmunoregulationimprovedin vivoinnovationinsightlife historymathematical modelmouse modelmulti-drug resistant pathogenmulti-scale modelingmultidisciplinarymultidrug-resistant Pseudomonas aeruginosamutantneutrophilnovelnovel therapeutic interventionoptimal control theorypathogenpathogenic bacteriapneumonia modelpredictive modelingpreventpublic health relevancerational designrespiratoryrespiratory pathogenresponsescale upsimulationspatiotemporalsynergismtraittreatment strategy
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Abstract
Multi-drug resistant (MDR) bacterial pathogens constitute a critical public health threat. The spread of
MDR pathogens in hospitals and in the environment has spurred a multidisciplinary response to develop
novel antibiotic alternatives. Bacteriophage (`phage') therapy represents a treatment strategy that can, in
principle, specifically eliminate MDR pathogens from animal hosts while minimizing off-target effects on
host cells and commensal bacteria. The successful compassionate use of phage therapy for critically ill
patients in the United States demonstrates a critical first-step towards large-scale translational deployment
of phage therapy. However, prior clinical trials of phage therapeutic efficacy have yielded equivocal
results, thereby raising the question: what are the core mechanisms underlying curative treatment of
respiratory infections by phage therapy? The use of phage-based therapy presumes that the direct killing
action of phage is responsible for pathogen elimination in vivo. In contrast, prior work of the investigators
showed that the outcome of in vivo phage therapeutic treatment of acute pneumonia in a murine host
depended critically on host immune state. The investigators combined population modeling and
experimental analysis to identify a mechanism of `immunophage synergy' to identify criteria when phage
therapy works and when it fails. Here, the project will combine population modeling, control theory, data-
driven computational simulations, in vitro experiments with phage, bacteria, and neutrophils, and in vivo
infection experiments in murine hosts to understand fundamental principles underlying curative treatment
of acute respiratory infections. This project will characterize the spatiotemporal drivers of synergistic
elimination in vivo as well as develop optimized combinations of phage strains, dosages, and timing to
avert therapeutic failure via the proliferation of phage-resistant bacterial mutants across a continuum of
immunodeficient hosts. The integrated and multidisciplinary research plans are designed to yield
fundamental insights into the mechanism of synergistic elimination of bacterial pathogens by phage and
innate effector cells as well as generalizable and rigorous approaches to optimized phage cocktail design
when immune responses are compromised.
期刊论文(13)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Disease-dependent interaction policies to support health and economic outcomes during the COVID-19 epidemic.
在 COVID-19 流行期间支持健康和经济成果的疾病相关互动政策。
DOI:
10.1101/2020.08.24.20180752
发表时间:
2020
期刊:
medRxiv : the preprint server for health sciences
影响因子:
--
作者:
[Li,Guanlin, Shivam,Shashwat, Hochberg,MichaelE, Wardi,Yorai, Weitz,JoshuaS]
通讯作者:
Weitz,JoshuaS
Inferring strain-level mutational drivers of phage-bacteria interaction phenotypes.
推断噬菌体-细菌相互作用表型的菌株水平突变驱动因素。
DOI:
10.1101/2024.01.08.574707
发表时间:
2024
期刊:
bioRxiv : the preprint server for biology
影响因子:
--
作者:
[Lucia-Sanz,Adriana, Peng,Shengyun, Leung,ChungYinJoey, Gupta,Animesh, Meyer,JustinR, Weitz,JoshuaS]
通讯作者:
Weitz,JoshuaS
DOI:
10.1016/j.epidem.2020.100392
发表时间:
2020-06-01
期刊:
EPIDEMICS
影响因子:
3.8
作者:
[Park, Sang Woo, Cornforth, Daniel M., Weitz, Joshua S.]
通讯作者:
Weitz, Joshua S.
DOI:
10.1007/s11538-020-00751-w
发表时间:
2020-06-12
期刊:
Bulletin of mathematical biology
影响因子:
3.5
作者:
[Li G, Leung CY, Wardi Y, Debarbieux L, Weitz JS]
通讯作者:
Weitz JS
Synergistic control of acute respiratory pathogens by bacteriophage and the innate immune response
-
批准号:9797736
-
项目类别:
-
资助金额:$50.17万
-
财政年份:2019
-
负责人:Laurent DEBARBIEUX
-
依托单位:
Synergistic control of acute respiratory pathogens by bacteriophage and the innate immune response
-
批准号:10461723
-
项目类别:
-
资助金额:$48.81万
-
财政年份:2019
-
负责人:Laurent DEBARBIEUX
-
依托单位:
Synergistic control of acute respiratory pathogens by bacteriophage and the innate immune response
-
批准号:10213594
-
项目类别:
-
资助金额:$48.1万
-
财政年份:2019
-
负责人:Laurent DEBARBIEUX
-
依托单位:
Synergistic control of acute respiratory pathogens by bacteriophage and the innate immune response
-
批准号:10000827
-
项目类别:
-
资助金额:$47.55万
-
财政年份:2019
-
负责人:Laurent DEBARBIEUX
-
依托单位:
海外基金